CASI Pharmaceuticals Inc. (CASI)
| Bid | 1.14 |
| Market Cap | 23.39M |
| Revenue (ttm) | 31.56M |
| Net Income (ttm) | -46.89M |
| EPS (ttm) | -2.89 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | -1.09 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.95 |
| Volume | 14,952 |
| Avg. Volume (20D) | 1,231,233 |
| Open | 1.58 |
| Previous Close | 1.58 |
| Day's Range | 1.51 - 1.58 |
| 52-Week Range | 1.09 - 7.50 |
| Beta | 0.72 |
| Ex-Dividend Date | n/a |
About CASI
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for CASI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
3 weeks ago · accessnewswire.com
CASI Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceSOUTH SAN FRANCISCO, CA / ACCESS Newswire / September 3, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for pati...
3 weeks ago · accessnewswire.com
CASI Pharmaceuticals Appoints Barbara Krebs-Pohl, PhD to Board of Directors- Industry veteran brings extensive senior level leadership and expertise in biologics development, strategic partnerships, mergers and acquisitions across biotech and large pharma organizations - Ope...
3 weeks ago · accessnewswire.com
CASI Pharmaceuticals Announces Second Quarter 2025 Business and Financial ResultsSOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / August 29, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies fo...
4 weeks ago · accessnewswire.com
CASI Pharmaceuticals to Participate at Cantor Global Healthcare Conference 2025SAN FRANCISCO, CA / ACCESS Newswire / August 28, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients wit...
